---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-008919"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:07:13.755812+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma acquires U.S. rights to PKU GOLIKE for $2.2M upfront plus milestones and 30% royalty

## Summary
- Acquired U.S. rights to PKU GOLIKE for $2.2M upfront, up to $2M milestones, and 30% royalty on net sales.
- PKU GOLIKE targets phenylketonuria (PKU) in an estimated $100M U.S. medical formula market.
- Deal expected to be accretive to 2024 earnings; peak sales forecast >$10M annually.
- Also acquired U.S. rights to line extensions for tyrosinemia, homocystinuria (launch 2025/2026) and right of first negotiation for RLF-OD032.
- Product complements Eton's metabolic franchise; promoted by existing sales force targeting metabolic geneticists.

## SEC filing metadata
- accession: 0001437749-24-008919
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924008919/0001437749-24-008919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924008919/eton20240318_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-008919
- JSON: https://secwatch.observer/filing/0001437749-24-008919.json
- Plain text: https://secwatch.observer/filing/0001437749-24-008919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.